Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| INTEGRA LIFESCIENCES HOLDINGS CORPIART · Entity 2707 | EVP & President, TR&DT | July 01, 2026 | July 06, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
INTEGRA LIFESCIENCES HOLDINGS CORP
Report date July 01, 2026 · Filed July 06, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 54,530 |
Reported balance
After 2026-07-01 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-07-01 · Grant · Acquired 11,180 · Balance 54,530 F1: Grant of restricted stock units ("RSUs") pursuant to the Integra LifeSciences Holdings Corporation Fifth Amended and Restated 2003 Equity Incentive Plan, as amended (the "Plan"). Each RSU represents a contingent right to receive one share of the Issuer's common stock. F2: All RSUs reported in this row were granted under the Plan and will vest in full on the second anniversary of the grant date, subject to the Reporting Person's continued service through such date. |
Filing footnotes · ownership attribution and instrument terms
F1: Grant of restricted stock units ("RSUs") pursuant to the Integra LifeSciences Holdings Corporation Fifth Amended and Restated 2003 Equity Incentive Plan, as amended (the "Plan"). Each RSU represents a contingent right to receive one share of the Issuer's common stock.
F2: All RSUs reported in this row were granted under the Plan and will vest in full on the second anniversary of the grant date, subject to the Reporting Person's continued service through such date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 13, 2021 Filed Mar 16, 2021 20:15 UTC | INTEGRA LIFESCIENCES HOLDINGS CORP IART · Entity 2707 | Tax withholdingCommon Stock | 210 | $68.10 | $14,301.00 |
DisclosureSEC source: 0001209191-21-020767 · doc4.xml · nonDerivative · entry 4 DAVIS ROBERT T. JR. · CIK 0001563606 · EVP & President, TT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,151 Read SEC document |
| March 13, 2021 Filed Mar 16, 2021 20:15 UTC | INTEGRA LIFESCIENCES HOLDINGS CORP IART · Entity 2707 | Tax withholdingCommon Stock | 288 | $68.10 | $19,612.80 |
DisclosureSEC source: 0001209191-21-020767 · doc4.xml · nonDerivative · entry 3 DAVIS ROBERT T. JR. · CIK 0001563606 · EVP & President, TT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,361 Read SEC document |
| March 13, 2021 Filed Mar 16, 2021 20:15 UTC | INTEGRA LIFESCIENCES HOLDINGS CORP IART · Entity 2707 | Tax withholdingCommon Stock | 208 | $68.10 | $14,164.80 |
DisclosureSEC source: 0001209191-21-020767 · doc4.xml · nonDerivative · entry 2 DAVIS ROBERT T. JR. · CIK 0001563606 · EVP & President, TT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,649 Read SEC document |
| March 12, 2021 Filed Mar 16, 2021 20:15 UTC | INTEGRA LIFESCIENCES HOLDINGS CORP IART · Entity 2707 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 9,232 | $0.00 Strike: $68.10 | $0.00 |
DisclosureSEC source: 0001209191-21-020767 · doc4.xml · derivative · entry 5 DAVIS ROBERT T. JR. · CIK 0001563606 · EVP & President, TT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,232 Underlying: Common Stock · 9,232 shares Expires 2029-03-12 F1 · derivative.exercise_date: 25% of the stock options vest every first, second, third and fourth anniversaries of the grant date of 3/12/2021. Read SEC document |
| March 12, 2021 Filed Mar 16, 2021 20:15 UTC | INTEGRA LIFESCIENCES HOLDINGS CORP IART · Entity 2707 | GrantCommon Stock | 3,063 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-020767 · doc4.xml · nonDerivative · entry 1 DAVIS ROBERT T. JR. · CIK 0001563606 · EVP & President, TT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,857 Read SEC document |
| February 25, 2021 Filed Feb 26, 2021 21:08 UTC | INTEGRA LIFESCIENCES HOLDINGS CORP IART · Entity 2707 | SaleCommon Stock | 24,941 | $69.48 | $1,732,963.03 |
DisclosureSEC source: 0001209191-21-014694 · doc4.xml · nonDerivative · entry 1 DAVIS ROBERT T. JR. · CIK 0001563606 · EVP & President, TT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,794 F1 · price: The price shown above represents the weighted average price of the shares sold. The range of sale prices was $69.01 to $70.99. Read SEC document |
| March 13, 2020 Filed Mar 17, 2020 20:12 UTC | INTEGRA LIFESCIENCES HOLDINGS CORP IART · Entity 2707 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 15,887 | $0.00 Strike: $43.39 | $0.00 |
DisclosureSEC source: 0001209191-20-019557 · doc4.xml · derivative · entry 8 DAVIS ROBERT T. JR. · CIK 0001563606 · CVP,PRES-ORTHO & TISSUE TECH 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,887 Underlying: Common Stock · 15,887 shares Expires 2028-03-13 F1 · derivative.exercise_date: 25% of the stock options vest every first, second, third and fourth anniversaries of the grant date of 3/13/2020. Read SEC document |
| March 13, 2020 Filed Mar 17, 2020 20:12 UTC | INTEGRA LIFESCIENCES HOLDINGS CORP IART · Entity 2707 | Tax withholdingCommon Stock | 1,121 | $43.39 | $48,640.19 |
DisclosureSEC source: 0001209191-20-019557 · doc4.xml · nonDerivative · entry 7 DAVIS ROBERT T. JR. · CIK 0001563606 · CVP,PRES-ORTHO & TISSUE TECH 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,735 Read SEC document |
| March 13, 2020 Filed Mar 17, 2020 20:12 UTC | INTEGRA LIFESCIENCES HOLDINGS CORP IART · Entity 2707 | Tax withholdingCommon Stock | 570 | $43.39 | $24,732.30 |
DisclosureSEC source: 0001209191-20-019557 · doc4.xml · nonDerivative · entry 6 DAVIS ROBERT T. JR. · CIK 0001563606 · CVP,PRES-ORTHO & TISSUE TECH 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,856 Read SEC document |
| March 13, 2020 Filed Mar 17, 2020 20:12 UTC | INTEGRA LIFESCIENCES HOLDINGS CORP IART · Entity 2707 | Tax withholdingCommon Stock | 547 | $43.39 | $23,734.33 |
DisclosureSEC source: 0001209191-20-019557 · doc4.xml · nonDerivative · entry 5 DAVIS ROBERT T. JR. · CIK 0001563606 · CVP,PRES-ORTHO & TISSUE TECH 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,426 Read SEC document |
| March 13, 2020 Filed Mar 17, 2020 20:12 UTC | INTEGRA LIFESCIENCES HOLDINGS CORP IART · Entity 2707 | GrantCommon Stock | 3,181 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-019557 · doc4.xml · nonDerivative · entry 4 DAVIS ROBERT T. JR. · CIK 0001563606 · CVP,PRES-ORTHO & TISSUE TECH 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,973 Read SEC document |
| March 13, 2020 Filed Mar 17, 2020 20:12 UTC | INTEGRA LIFESCIENCES HOLDINGS CORP IART · Entity 2707 | Tax withholdingCommon Stock | 226 | $43.39 | $9,806.14 |
DisclosureSEC source: 0001209191-20-019557 · doc4.xml · nonDerivative · entry 3 DAVIS ROBERT T. JR. · CIK 0001563606 · CVP,PRES-ORTHO & TISSUE TECH 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,792 Read SEC document |
| March 13, 2020 Filed Mar 17, 2020 20:12 UTC | INTEGRA LIFESCIENCES HOLDINGS CORP IART · Entity 2707 | Tax withholdingCommon Stock | 235 | $43.39 | $10,196.65 |
DisclosureSEC source: 0001209191-20-019557 · doc4.xml · nonDerivative · entry 2 DAVIS ROBERT T. JR. · CIK 0001563606 · CVP,PRES-ORTHO & TISSUE TECH 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,018 Read SEC document |
| March 13, 2020 Filed Mar 17, 2020 20:12 UTC | INTEGRA LIFESCIENCES HOLDINGS CORP IART · Entity 2707 | Tax withholdingCommon Stock | 300 | $43.39 | $13,017.00 |
DisclosureSEC source: 0001209191-20-019557 · doc4.xml · nonDerivative · entry 1 DAVIS ROBERT T. JR. · CIK 0001563606 · CVP,PRES-ORTHO & TISSUE TECH 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,253 Read SEC document |
| February 13, 2020 Filed Feb 18, 2020 21:55 UTC | INTEGRA LIFESCIENCES HOLDINGS CORP IART · Entity 2707 | GrantCommon Stock | 1,854 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-010223 · doc4.xml · nonDerivative · entry 3 DAVIS ROBERT T. JR. · CIK 0001563606 · CVP,PRES-ORTHO & TISSUE TECH 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,553 F3 · shares: On February 13, 2020, the Compensation Committee certified that the Company achieved its performance goal for fiscal year 2019 under the March 13, 2019 performance stock award at or above the threshold level based on annual organic revenue growth over the prior fiscal year. Accordingly, 33% of the shares will vest on March 13, 2020 at 97% of target, the first anniversary of the grant date. Read SEC document |
| February 13, 2020 Filed Feb 18, 2020 21:55 UTC | INTEGRA LIFESCIENCES HOLDINGS CORP IART · Entity 2707 | GrantCommon Stock | 1,778 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-010223 · doc4.xml · nonDerivative · entry 2 DAVIS ROBERT T. JR. · CIK 0001563606 · CVP,PRES-ORTHO & TISSUE TECH 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,699 F2 · shares: On February 13, 2020, the Compensation Committee certified that the Company achieved its performance goal for fiscal year 2019 under the March 13, 2018 performance stock award at or above the threshold level based on annual organic revenue growth over the prior fiscal year. Accordingly, 33% of the shares will vest on March 13, 2020 at 97% of target, the second anniversary of the grant date. Read SEC document |
| February 13, 2020 Filed Feb 18, 2020 21:55 UTC | INTEGRA LIFESCIENCES HOLDINGS CORP IART · Entity 2707 | GrantCommon Stock | 3,649 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-010223 · doc4.xml · nonDerivative · entry 1 DAVIS ROBERT T. JR. · CIK 0001563606 · CVP,PRES-ORTHO & TISSUE TECH 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,921 F1 · shares: On February 13, 2020, the Compensation Committee certified that the Company achieved its performance goal for fiscal year 2019, at least 9% and up to a maximum of 33% cumulative increase in annual revenue over the 2016 fiscal year, under the March 13, 2017 Performance Stock Award. Accordingly, 34% of the shares will vest on March 13, 2020 at 150% of target, the third anniversary of the grant date. Read SEC document |
| July 24, 2019 Filed Jul 26, 2019 20:14 UTC | INTEGRA LIFESCIENCES HOLDINGS CORP IART · Entity 2707 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 5,052 | $0.00 Strike: $32.59 | $0.00 |
DisclosureSEC source: 0001209191-19-043330 · doc4.xml · derivative · entry 7 DAVIS ROBERT T. JR. · CIK 0001563606 · CVP,PRES-ORTHO & TISSUE TECH 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,736 Underlying: Common Stock · 5,052 shares Expires 2024-03-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were affected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person. F4 · derivative.exercise_date: 25% of the stock options vest every first, second, third and fourth anniversaries of the grant date of 3/14/2016. F5 · balance_after: In accordance with the terms of the stock option plan, the exercise price of the option and number of shares subject to the option have been adjusted to reflect the two-for-one stock split that occurred on December 21, 2016. Read SEC document |
| July 24, 2019 Filed Jul 26, 2019 20:14 UTC | INTEGRA LIFESCIENCES HOLDINGS CORP IART · Entity 2707 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 4,698 | $0.00 Strike: $26.87 | $0.00 |
DisclosureSEC source: 0001209191-19-043330 · doc4.xml · derivative · entry 6 DAVIS ROBERT T. JR. · CIK 0001563606 · CVP,PRES-ORTHO & TISSUE TECH 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,566 Underlying: Common Stock · 4,698 shares Expires 2023-03-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were affected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person. F2 · derivative.exercise_date: 25% of the shares of stock options will vest each of the first, second, third and fourth anniversaries of the grant date of 03/23/2015. F3 · balance_after: This stock option was previously reported as covering 2,710 shares of common stock at an exercise price of $62.10 per share. In accordance with the terms of the stock option plan, the exercise price of the option and number of shares subject to the option have been adjusted to reflect the two-for-one stock split that occurred on December 21, 2016. Read SEC document |
| July 24, 2019 Filed Jul 26, 2019 20:14 UTC | INTEGRA LIFESCIENCES HOLDINGS CORP IART · Entity 2707 | SaleCommon Stock | 5,052 | $63.00 | $318,276.00 |
DisclosureSEC source: 0001209191-19-043330 · doc4.xml · nonDerivative · entry 5 DAVIS ROBERT T. JR. · CIK 0001563606 · CVP,PRES-ORTHO & TISSUE TECH 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,272 F1 · kind: The transactions reported in this Form 4 were affected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person. Read SEC document |
| July 24, 2019 Filed Jul 26, 2019 20:14 UTC | INTEGRA LIFESCIENCES HOLDINGS CORP IART · Entity 2707 | Exercise / conversionCommon Stock | 5,052 | $32.59 | $164,619.42 |
DisclosureSEC source: 0001209191-19-043330 · doc4.xml · nonDerivative · entry 4 DAVIS ROBERT T. JR. · CIK 0001563606 · CVP,PRES-ORTHO & TISSUE TECH 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,324 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were affected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person. Read SEC document |
| July 24, 2019 Filed Jul 26, 2019 20:14 UTC | INTEGRA LIFESCIENCES HOLDINGS CORP IART · Entity 2707 | SaleCommon Stock | 4,698 | $63.00 | $295,974.00 |
DisclosureSEC source: 0001209191-19-043330 · doc4.xml · nonDerivative · entry 3 DAVIS ROBERT T. JR. · CIK 0001563606 · CVP,PRES-ORTHO & TISSUE TECH 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,272 F1 · kind: The transactions reported in this Form 4 were affected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person. Read SEC document |
| July 24, 2019 Filed Jul 26, 2019 20:14 UTC | INTEGRA LIFESCIENCES HOLDINGS CORP IART · Entity 2707 | Exercise / conversionCommon Stock | 4,698 | $26.87 | $126,211.77 |
DisclosureSEC source: 0001209191-19-043330 · doc4.xml · nonDerivative · entry 2 DAVIS ROBERT T. JR. · CIK 0001563606 · CVP,PRES-ORTHO & TISSUE TECH 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,970 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were affected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person. Read SEC document |
| July 24, 2019 Filed Jul 26, 2019 20:14 UTC | INTEGRA LIFESCIENCES HOLDINGS CORP IART · Entity 2707 | SaleCommon Stock | 11,234 | $63.14 | $709,258.59 |
DisclosureSEC source: 0001209191-19-043330 · doc4.xml · nonDerivative · entry 1 DAVIS ROBERT T. JR. · CIK 0001563606 · CVP,PRES-ORTHO & TISSUE TECH 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,272 F1 · kind: The transactions reported in this Form 4 were affected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person. F1 · price: The transactions reported in this Form 4 were affected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person. Read SEC document |
| March 14, 2019 Filed Mar 15, 2019 21:20 UTC | INTEGRA LIFESCIENCES HOLDINGS CORP IART · Entity 2707 | Tax withholdingCommon Stock | 309 | $56.14 | $17,347.26 |
DisclosureSEC source: 0001209191-19-019757 · doc4.xml · nonDerivative · entry 7 DAVIS ROBERT T. JR. · CIK 0001563606 · CVP,PRES-ORTHO & TISSUE TECH 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,506 Read SEC document |
| March 14, 2019 Filed Mar 15, 2019 21:20 UTC | INTEGRA LIFESCIENCES HOLDINGS CORP IART · Entity 2707 | Tax withholdingCommon Stock | 1,155 | $56.14 | $64,841.70 |
DisclosureSEC source: 0001209191-19-019757 · doc4.xml · nonDerivative · entry 6 DAVIS ROBERT T. JR. · CIK 0001563606 · CVP,PRES-ORTHO & TISSUE TECH 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,815 Read SEC document |
| March 13, 2019 Filed Mar 15, 2019 21:20 UTC | INTEGRA LIFESCIENCES HOLDINGS CORP IART · Entity 2707 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 10,373 | $0.00 Strike: $55.91 | $0.00 |
DisclosureSEC source: 0001209191-19-019757 · doc4.xml · derivative · entry 8 DAVIS ROBERT T. JR. · CIK 0001563606 · CVP,PRES-ORTHO & TISSUE TECH 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,373 Underlying: Common Stock · 10,373 shares Expires 2027-03-13 F1 · derivative.exercise_date: 25% of the stock options vest every first, second, third and fourth anniversaries of the grant date of 3/13/2019. Read SEC document |
| March 13, 2019 Filed Mar 15, 2019 21:20 UTC | INTEGRA LIFESCIENCES HOLDINGS CORP IART · Entity 2707 | GrantCommon Stock | 2,318 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-019757 · doc4.xml · nonDerivative · entry 5 DAVIS ROBERT T. JR. · CIK 0001563606 · CVP,PRES-ORTHO & TISSUE TECH 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,970 Read SEC document |
| March 13, 2019 Filed Mar 15, 2019 21:20 UTC | INTEGRA LIFESCIENCES HOLDINGS CORP IART · Entity 2707 | Tax withholdingCommon Stock | 226 | $55.91 | $12,635.66 |
DisclosureSEC source: 0001209191-19-019757 · doc4.xml · nonDerivative · entry 4 DAVIS ROBERT T. JR. · CIK 0001563606 · CVP,PRES-ORTHO & TISSUE TECH 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,652 Read SEC document |
| March 13, 2019 Filed Mar 15, 2019 21:20 UTC | INTEGRA LIFESCIENCES HOLDINGS CORP IART · Entity 2707 | Tax withholdingCommon Stock | 290 | $55.91 | $16,213.90 |
DisclosureSEC source: 0001209191-19-019757 · doc4.xml · nonDerivative · entry 3 DAVIS ROBERT T. JR. · CIK 0001563606 · CVP,PRES-ORTHO & TISSUE TECH 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,878 Read SEC document |
| March 13, 2019 Filed Mar 15, 2019 21:20 UTC | INTEGRA LIFESCIENCES HOLDINGS CORP IART · Entity 2707 | Tax withholdingCommon Stock | 505 | $55.91 | $28,234.55 |
DisclosureSEC source: 0001209191-19-019757 · doc4.xml · nonDerivative · entry 2 DAVIS ROBERT T. JR. · CIK 0001563606 · CVP,PRES-ORTHO & TISSUE TECH 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,168 Read SEC document |
| March 13, 2019 Filed Mar 15, 2019 21:20 UTC | INTEGRA LIFESCIENCES HOLDINGS CORP IART · Entity 2707 | Tax withholdingCommon Stock | 1,088 | $55.91 | $60,830.08 |
DisclosureSEC source: 0001209191-19-019757 · doc4.xml · nonDerivative · entry 1 DAVIS ROBERT T. JR. · CIK 0001563606 · CVP,PRES-ORTHO & TISSUE TECH 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,673 Read SEC document |
| February 14, 2019 Filed Feb 19, 2019 22:05 UTC | INTEGRA LIFESCIENCES HOLDINGS CORP IART · Entity 2707 | GrantCommon Stock | 1,641 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-011174 · doc4.xml · nonDerivative · entry 3 DAVIS ROBERT T. JR. · CIK 0001563606 · CVP,PRES-ORTHO & TISSUE TECH 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,761 F3 · shares: On February 14, 2019, the Compensation Committee certified that the Company achieved its performance goal for fiscal year 2018 under the March 13, 2018 performance stock award at or above the threshold level based on annual organic revenue growth over the prior fiscal year. Accordingly, 33% of the shares will vest on March 13, 2019 at 89.5% of target, the first anniversary of the grant date. Read SEC document |
| February 14, 2019 Filed Feb 19, 2019 22:05 UTC | INTEGRA LIFESCIENCES HOLDINGS CORP IART · Entity 2707 | GrantCommon Stock | 3,541 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-011174 · doc4.xml · nonDerivative · entry 2 DAVIS ROBERT T. JR. · CIK 0001563606 · CVP,PRES-ORTHO & TISSUE TECH 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,120 F2 · shares: On February 14, 2019, the Compensation Committee certified that the Company achieved its performance goal for fiscal year 2018, at least 3% and up to a maximum of 11% increase in annual revenue over the prior fiscal year, under the March 13, 2017 Performance Stock Award. Accordingly, 33% of the shares will vest on March 13, 2019 at 150% of target, the second anniversary of the grant date. Read SEC document |
| February 14, 2019 Filed Feb 19, 2019 22:05 UTC | INTEGRA LIFESCIENCES HOLDINGS CORP IART · Entity 2707 | GrantCommon Stock | 3,759 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-011174 · doc4.xml · nonDerivative · entry 1 DAVIS ROBERT T. JR. · CIK 0001563606 · CVP,PRES-ORTHO & TISSUE TECH 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,579 F1 · shares: On February 14, 2019, the Compensation Committee certified that the Company achieved its performance goal for fiscal year 2018, at least 3% and up to a maximum of 11% increase in annual revenue over the prior fiscal year, under the March 14, 2016 Performance Stock Award. Accordingly, 34% of the shares will vest on March 14, 2019 at 150% of target, the third anniversary of the grant date. Read SEC document |
| March 23, 2018 Filed Mar 27, 2018 21:35 UTC | INTEGRA LIFESCIENCES HOLDINGS CORP IART · Entity 2707 | Tax withholdingCommon Stock | 507 | $54.15 | $27,454.05 |
DisclosureSEC source: 0001209191-18-021799 · doc4.xml · nonDerivative · entry 2 DAVIS ROBERT T. JR. · CIK 0001563606 · CVP,PRES-ORTHO & TISSUE TECH 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,820 Read SEC document |
| March 23, 2018 Filed Mar 27, 2018 21:35 UTC | INTEGRA LIFESCIENCES HOLDINGS CORP IART · Entity 2707 | Tax withholdingCommon Stock | 507 | $54.15 | $27,454.05 |
DisclosureSEC source: 0001209191-18-021799 · doc4.xml · nonDerivative · entry 1 DAVIS ROBERT T. JR. · CIK 0001563606 · CVP,PRES-ORTHO & TISSUE TECH 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,327 Read SEC document |
| March 14, 2018 Filed Mar 15, 2018 20:21 UTC | INTEGRA LIFESCIENCES HOLDINGS CORP IART · Entity 2707 | Tax withholdingCommon Stock | 299 | $56.14 | $16,785.86 |
DisclosureSEC source: 0001209191-18-019839 · doc4.xml · nonDerivative · entry 5 DAVIS ROBERT T. JR. · CIK 0001563606 · CVP,PRES-ORTHO & TISSUE TECH 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,834 Read SEC document |
| March 14, 2018 Filed Mar 15, 2018 20:21 UTC | INTEGRA LIFESCIENCES HOLDINGS CORP IART · Entity 2707 | Tax withholdingCommon Stock | 1,120 | $56.14 | $62,876.80 |
DisclosureSEC source: 0001209191-18-019839 · doc4.xml · nonDerivative · entry 4 DAVIS ROBERT T. JR. · CIK 0001563606 · CVP,PRES-ORTHO & TISSUE TECH 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,133 Read SEC document |
| March 13, 2018 Filed Mar 15, 2018 20:21 UTC | INTEGRA LIFESCIENCES HOLDINGS CORP IART · Entity 2707 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 8,609 | $0.00 Strike: $56.23 | $0.00 |
DisclosureSEC source: 0001209191-18-019839 · doc4.xml · derivative · entry 6 DAVIS ROBERT T. JR. · CIK 0001563606 · CVP,PRES-ORTHO & TISSUE TECH 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,609 Underlying: Common Stock · 8,609 shares Expires 2026-03-13 F1 · derivative.exercise_date: 25% of the stock options vest every first, second, third and fourth anniversaries of the grant date of 3/13/2018. Read SEC document |
| March 13, 2018 Filed Mar 15, 2018 20:21 UTC | INTEGRA LIFESCIENCES HOLDINGS CORP IART · Entity 2707 | Tax withholdingCommon Stock | 290 | $56.23 | $16,306.70 |
DisclosureSEC source: 0001209191-18-019839 · doc4.xml · nonDerivative · entry 3 DAVIS ROBERT T. JR. · CIK 0001563606 · CVP,PRES-ORTHO & TISSUE TECH 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,253 Read SEC document |
| March 13, 2018 Filed Mar 15, 2018 20:21 UTC | INTEGRA LIFESCIENCES HOLDINGS CORP IART · Entity 2707 | GrantCommon Stock | 2,224 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-019839 · doc4.xml · nonDerivative · entry 2 DAVIS ROBERT T. JR. · CIK 0001563606 · CVP,PRES-ORTHO & TISSUE TECH 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,543 Read SEC document |
| March 13, 2018 Filed Mar 15, 2018 20:21 UTC | INTEGRA LIFESCIENCES HOLDINGS CORP IART · Entity 2707 | Tax withholdingCommon Stock | 1,088 | $56.23 | $61,178.24 |
DisclosureSEC source: 0001209191-18-019839 · doc4.xml · nonDerivative · entry 1 DAVIS ROBERT T. JR. · CIK 0001563606 · CVP,PRES-ORTHO & TISSUE TECH 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,319 Read SEC document |
| February 15, 2018 Filed Feb 20, 2018 21:27 UTC | INTEGRA LIFESCIENCES HOLDINGS CORP IART · Entity 2707 | GrantCommon Stock | 3,541 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-011349 · doc4.xml · nonDerivative · entry 3 DAVIS ROBERT T. JR. · CIK 0001563606 · CVP,PRES-ORTHO & TISSUE TECH 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,407 F3 · shares: On February 15, 2018, the Compensation Committee certified that the Company achieved its performance goal for fiscal year 2017, at least 3% and up to a maximum of 11% increase in annual revenue over the prior fiscal year, under the March 13, 2017 Performance Stock Award. Accordingly, 33% of the shares will vest on March 13, 2018 at 150% target, the first anniversary of the grant date. Read SEC document |
| February 15, 2018 Filed Feb 20, 2018 21:27 UTC | INTEGRA LIFESCIENCES HOLDINGS CORP IART · Entity 2707 | GrantCommon Stock | 3,645 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-011349 · doc4.xml · nonDerivative · entry 2 DAVIS ROBERT T. JR. · CIK 0001563606 · CVP,PRES-ORTHO & TISSUE TECH 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,866 F2 · shares: On February 15, 2018, the Compensation Committee certified that the Company achieved its performance goal for fiscal year 2017, at least 3% and up to a maximum of 11% increase in annual revenue over the prior fiscal year, under the March 14, 2016 Performance Stock Award. Accordingly, 33% of the shares will vest on March 14, 2018 at 150% target, the second anniversary of the grant date. Read SEC document |
| February 15, 2018 Filed Feb 20, 2018 21:27 UTC | INTEGRA LIFESCIENCES HOLDINGS CORP IART · Entity 2707 | GrantCommon Stock | 1,650 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-011349 · doc4.xml · nonDerivative · entry 1 DAVIS ROBERT T. JR. · CIK 0001563606 · CVP,PRES-ORTHO & TISSUE TECH 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,221 F1 · shares: On February 15, 2018, the Compensation Committee certified that the Company achieved its performance goal for fiscal year 2017, at least a 3% increase in annual revenue over the prior fiscal year, under the March 23, 2015 Performance Stock Award. Accordingly, 34% of the shares will vest on March 23, 2018, the third anniversary of the grant date. Read SEC document |
| March 24, 2017 Filed Mar 27, 2017 23:15 UTC | INTEGRA LIFESCIENCES HOLDINGS CORP IART · Entity 2707 | Tax withholdingCommon Stock | 794 | $42.74 | $33,935.56 |
DisclosureSEC source: 0001209191-17-023008 · doc4.xml · nonDerivative · entry 4 DAVIS ROBERT T. JR. · CIK 0001563606 · CVP,PRES-ORTHO & TISSUE TECH 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,571 Read SEC document |
| March 24, 2017 Filed Mar 27, 2017 23:15 UTC | INTEGRA LIFESCIENCES HOLDINGS CORP IART · Entity 2707 | Tax withholdingCommon Stock | 794 | $42.74 | $33,935.56 |
DisclosureSEC source: 0001209191-17-023008 · doc4.xml · nonDerivative · entry 3 DAVIS ROBERT T. JR. · CIK 0001563606 · CVP,PRES-ORTHO & TISSUE TECH 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,365 Read SEC document |
| March 23, 2017 Filed Mar 27, 2017 23:15 UTC | INTEGRA LIFESCIENCES HOLDINGS CORP IART · Entity 2707 | Tax withholdingCommon Stock | 541 | $42.35 | $22,911.35 |
DisclosureSEC source: 0001209191-17-023008 · doc4.xml · nonDerivative · entry 2 DAVIS ROBERT T. JR. · CIK 0001563606 · CVP,PRES-ORTHO & TISSUE TECH 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,159 Read SEC document |
| March 23, 2017 Filed Mar 27, 2017 23:15 UTC | INTEGRA LIFESCIENCES HOLDINGS CORP IART · Entity 2707 | Tax withholdingCommon Stock | 541 | $42.35 | $22,911.35 |
DisclosureSEC source: 0001209191-17-023008 · doc4.xml · nonDerivative · entry 1 DAVIS ROBERT T. JR. · CIK 0001563606 · CVP,PRES-ORTHO & TISSUE TECH 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,700 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.